US-based healthcare company Baxter International has commercially launched five new injectable pharmaceutical products in the US.
The five products, launched as part of the company’s US pharmaceuticals portfolio include Micafungin, Cyclophosphamide, Pantoprazole Sodium, Cefazolin, and Levetiracetam.
Micafungin in 0.9% Sodium Chloride Injection is indicated for preventing and treating Candida infections in people undergoing hematopoietic stem cell transplantation.
The drug uses the US pharmaceutical company’s unique container technology.
Baxter launched Cyclophosphamide Injection, an alkylating drug, in 500mg/2.5 mL and 1000mg/5 mL strengths in multiple-dose vials, which requires further dilution before use.
It is indicated for the treatment of adults and paediatric patients with various malignant diseases and is frequently used in combination with other oncology medications.
Pantoprazole Sodium in 0.9% Sodium Chloride Injection is a proton pump inhibitor offered in 40mg/50mL, 40mg/100mL and 80mg/100mL strengths.
The drug is intended for the short-term treatment of a type of gastroesophageal reflux disease (GERD) in adults.
It is indicated for the treatment of GERD associated with erosive esophagitis (EE) and pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome.
Baxter said it is offering Cefazolin in Dextrose Injection, USP in 1g/50mL, 2g/100mL and 3g/150mL strengths.
The single-dose, first-generation cephalosporin antibacterial is indicated for adults and children to prevent and treat infections from various susceptible organisms.
Levetiracetam in Sodium Chloride Injection is an anti-epileptic drug offered in 500mg/100mL, 1000mg/100mL and 1500mg/100mL strengths.
The drug is indicated for adjunct therapy in adult patients for partial onset seizures, myoclonic seizures, and tonic-clonic seizures.
Baxter pharmaceuticals executive vice president and group president Alok Sonig said: “Our pharmaceuticals teams are relentlessly focused on bringing differentiated products to market that support our customers in helping to address vital patient needs.
“We look forward to further accelerating our impact with a robust innovation pipeline across our key therapeutic areas, including critical care, anti-infectives, pain and oncology.”
Baxter said the currently launched commonly prescribed drugs in ready-to-use formats of standard concentrations may provide operational efficiencies for healthcare providers.
According to the company, compounding a drug is a manual process that requires oversight by the pharmacy staff, and a ready-to-use product can simplify the preparation process.
The ready-to-use product may reduce the chance of contamination and avoid the potential errors that may occur when medications are compounded.
The five newly launched products, together with the five launches announced in April this year, bring the total number of injectable products launched in the US this year to ten.
